2025-12-31 - Analysis Report
Okay, here's the analysis of Tempus AI (TEM) based on the data provided.

**1. Return Rate Comparison**

*   **Company Overview:** Tempus AI Inc. leverages AI and data to personalize healthcare, particularly in oncology.
*   **TEM Cumulative Return:** 7.80%
*   **S&P 500 (VOO) Cumulative Return:** 31.44%
*   **Divergence:** -20.5 (Relative Divergence: 17.5)

**Analysis:** TEM has significantly underperformed the S&P 500 over the period examined. The divergence of -20.5 indicates a substantial difference in returns. A relative divergence of 17.5 suggests that the current divergence is near the lower end of its historical range.

**Alpha, Beta Analysis**

| Year      | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
| --------- | ------ | ------ | ------ | ---- | ------ |
| 2023-2025 | 8.0%   | 76.7%  | -23.0% | 0.3  | 10.7   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** A CAGR of 8.0% suggests moderate growth over the specified period.
*   **MDD (Maximum Drawdown):** A very high MDD of 76.7% indicates significant volatility and potential for large losses.
*   **Alpha:** A negative alpha of -23.0% means TEM has underperformed its benchmark (likely the S&P 500) on a risk-adjusted basis.
*   **Beta:** A low beta of 0.3 suggests TEM is significantly less volatile than the overall market.
*   **Cap(B):** The company has a market capitalization of $10.7 billion.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** $60.39
*   **Previous Close:** $61.47
*   **Change:** -1.76%
*   **5-day SMA:** $62.71
*   **20-day SMA:** $69.16
*   **60-day SMA:** $77.99

**Analysis:** TEM's stock price is currently below all three moving averages, indicating a short-term downward trend. The decreasing price and recent negative change suggest selling pressure.

**3. Indicators Analysis**

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment)
*   **RSI (Relative Strength Index):** 16.19
*   **PPO (Percentage Price Oscillator):** -1.03
*   **Hybrid Signal:** Buy 100% of cash (14 shares - Very Safe - MRI:0.90) Monthly invest 5.0% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** -2.8 (short-term decline)
*   **Expected Return:** NaN

**Analysis:**

*   The **MRI of 0.9** suggests TEM is a medium risk investment, but still in the higher end of the medium area.
*   The **RSI of 16.19** indicates that the stock is heavily oversold, potentially signaling a possible rebound.
*   The **PPO of -1.03** confirms the downward trend, with the short-term moving average below the long-term moving average.
*   The **Hybrid Signal** recommends a buy, indicating that according to the indicators and MRI, TEM might be a good investment at the moment.
*   The **recent relative divergence change of -2.8** confirms short-term negative price momentum, but it is expected as the price decrease is also an important factor of the MRI.
*   The **Expected Return being NaN** means this metric could not be reliably calculated, but that long term expectation might be positive.

**4. Recent News & Significant Events**

*   **Positive Outlook (AI Boom):** Some articles highlight the potential gains for MedTech stocks like TEM from the AI boom.
*   **Pivotal Transition:** One article discusses whether TEM is a Buy, Hold, or Sell during a crucial transition period. This suggests uncertainty but also potential for positive change.
*   **FDA Clearance & Price Drop:** One article suggests TEM opinions are conflicted on FDA clearance, and it mentions a price drop, indicating negative sentiment.
*   **Building Scale with Near-Term Risks:** An article from The Globe and Mail suggests TEM is focused on long-term growth, but faces immediate risks.
*   **Comparison to HIMS:** Finviz compared TEM vs. HIMS to see which medical info systems stock offers greater upside.
*   **Up 87% in 2025**: An article on TIKR.com reported TEM stock is up 87% in 2025, contrasting with other negative news.

**Analysis:** The news is mixed. While some articles mention the potential benefits of AI and highlight TEM's growth in 2025, others point to near-term risks, a price drop, and uncertainty surrounding a pivotal transition. This suggests a company with potential but also significant challenges to navigate.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (~2.14 on a scale of 1-5)
*   **Opinions:** 12 analysts
*   **Target Price (avg/high/low):** $88.92 / $105.00 / $80.00

**Analysis:** Analysts are generally optimistic about TEM, with a "Buy" consensus and a significant upside potential based on target prices. This contrasts with some of the more cautious viewpoints expressed in recent news articles.

**5. Comprehensive Analysis**

TEM presents a mixed investment picture. On one hand, the company operates in a promising sector (AI-driven healthcare), has a strong analyst consensus ("Buy"), and has shown growth in 2025. The MRI is also quite high at 0.9. On the other hand, TEM has significantly underperformed the S&P 500, exhibits high volatility (MDD of 76.7%), and faces near-term risks and uncertainties as highlighted in recent news articles. Recent price action is also bearish, with the stock trading below its moving averages and exhibiting a low RSI indicating an oversold state. The recent relative divergence change indicates short-term negative momentum.

**In summary:** TEM is a high-risk, high-reward investment. The positive analyst outlook and potential for growth in the AI-driven healthcare sector are attractive. However, investors should be aware of the significant volatility and near-term challenges facing the company. A rebound might be expected due to the very low RSI. The mixed news suggests careful monitoring is essential.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.